{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:57:02Z","timestamp":1788195422538,"version":"build-2803163510"},"reference-count":106,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","award":["N42\/DBS\/000066"],"award-info":[{"award-number":["N42\/DBS\/000066"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Fibromyalgia is a disease characterized by lowered pain threshold, mood disorders, and decreased muscular strength. It results from a complex dysfunction of the nervous system and due to unknown etiology, its diagnosis, treatment, and prevention are a serious challenge for contemporary medicine. Impaired serotonergic and dopaminergic neurotransmission are regarded as key factors contributing to fibromyalgia. The present research assessed the effect of serotonergic and dopaminergic system modulators (vortioxetine and ropinirole, respectively) on the pain threshold, depressive-like behavior, anxiety, and motor functions of mice with fibromyalgia-like symptoms induced by subcutaneous reserpine (0.25 mg\/kg). By depleting serotonin and dopamine in the mouse brain, reserpine induced symptoms of human fibromyalgia. Intraperitoneal administration of vortioxetine and ropinirole at the dose of 10 mg\/kg alleviated tactile allodynia. At 5 and 10 mg\/kg ropinirole showed antidepressant-like properties, while vortioxetine had anxiolytic-like properties. None of these drugs influenced muscle strength but reserpine reduced locomotor activity of mice. Concluding, in the mouse model of fibromyalgia vortioxetine and ropinirole markedly reduced pain. These drugs affected emotional processes of mice in a distinct manner. Hence, these two repurposed drugs should be considered as potential drug candidates for fibromyalgia. The selection of a specific drug should depend on patient\u2019s key symptoms.<\/jats:p>","DOI":"10.3390\/molecules26082398","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T13:58:04Z","timestamp":1618927084000},"page":"2398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2\/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-5393","authenticated-orcid":false,"given":"Kinga","family":"Sa\u0142at","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Furga\u0142a-Wojas","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/14038196.2010.546880","article-title":"\u201cI\u2019m tired of being tired\u201d\u2014Fatigue as experienced by women with fibromyalgia","volume":"13","author":"Sallinen","year":"2011","journal-title":"Adv. Physiother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1359105317736577","article-title":"Somatic symptom presentations in women with fibromyalgia are differentially associated with elevated depression and anxiety","volume":"25","author":"Hadlandsmyth","year":"2017","journal-title":"J. Health Psychol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijchp.2019.02.002","article-title":"Cognitive rigidity in patients with depression and fibromyalgia","volume":"9","author":"Aguilera","year":"2019","journal-title":"Int. J. Clin. Health Psychol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"H\u00e4user, W., Jung, E., Erbsl\u00f6h-M\u00f6ller, B., Gesmann, M., K\u00fchn-Becker, H., Petermann, F., Langhorst, J., Thoma, R., Weiss, T., and Wolfe, F. (2012). The German fibromyalgia consumer reports\u2014A cross-sectional survey. BMC Musculoskelet. Disord., 13.","DOI":"10.1186\/1471-2474-13-74"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bennett, R.M., Jones, J., Turk, D.C., Russell, I.J., and Matallana, L. (2007). An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet. Disord., 8.","DOI":"10.1186\/1471-2474-8-27"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ablin, J., Fitzcharles, M.A., Buskila, D., Shir, Y., Sommer, C., and H\u00e4user, W. (2013). Treatment of fibromyalgia syndrome: Recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid. Based Complement. Altern. Med., 2013.","DOI":"10.1155\/2013\/485272"},{"key":"ref_8","unstructured":"(2020, February 24). Available online: https:\/\/www.rheumatology.org\/I-Am-A\/Patient-Caregiver\/Diseases-Conditions\/Fibromyalgia."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbr.2016.10.004","article-title":"Prevalence of fibromyalgia: Literature review update","volume":"57","author":"Marques","year":"2017","journal-title":"Rev. Bras. Reumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.33338","article-title":"Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10067-009-1147-6","article-title":"Risk factors for fibromyalgia: The role of violence against women","volume":"28","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.09.008","article-title":"Pathophysiology of Fibromyalgia","volume":"122","author":"Bradley","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.159.8.777","article-title":"Fibromyalgia Syndrome a Decade Later: What Have We Learned?","volume":"159","author":"Goldenberg","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1521-6942(03)00042-1","article-title":"The epidemiology of chronic generalized musculoskeletal pain","volume":"17","author":"Gran","year":"2003","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e22147","DOI":"10.1002\/syn.22147","article-title":"5\u2032UTR polymorphism in the serotonergic receptor HTR3A gene is differently associated with striatal Dopamine D2\/D3 receptor availability in the right putamen in Fibromyalgia patients and healthy controls-Preliminary evidence","volume":"74","author":"Ledermann","year":"2020","journal-title":"Synapse"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11926-005-0021-z","article-title":"The role of life stress in fibromyalgia","volume":"7","author":"Egle","year":"2005","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.10893","article-title":"Neurophysiologic evidence for a central sensitization in patients with fibromyalgia","volume":"48","author":"Desmeules","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/keg075","article-title":"Inaccuracy in the diagnosis of fibromyalgia syndrome: Analysis of referrals","volume":"42","author":"Fitzcharles","year":"2003","journal-title":"Rheumatology"},{"key":"ref_19","first-page":"6","article-title":"Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment","volume":"75","author":"Mease","year":"2005","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ynpai.2017.04.003","article-title":"A new aspect of chronic pain as a lifestyle-related disease","volume":"1","author":"Senba","year":"2017","journal-title":"Neurobiol. Pain"},{"key":"ref_21","first-page":"504","article-title":"Fibromyalgiesyndrom Basiswissen, Diagnostik und Therapie [Fibromyalgia syndrome: Basic knowledge, diagnosis and treatment]","volume":"39","year":"2016","journal-title":"Med. Monatsschr. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","article-title":"Serotonin: A never-ending story","volume":"753","author":"Olivier","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","article-title":"The serotonergic system and cognitive function","volume":"7","author":"Pivac","year":"2016","journal-title":"Transl. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00207454.2019.1664510","article-title":"Duloxetine for pain in fibromyalgia in adults: A systematic review and a meta-analysis","volume":"130","author":"Lian","year":"2020","journal-title":"Int. J. Neurosci."},{"key":"ref_25","first-page":"CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia","volume":"2","author":"Welsch","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/164_2018_164","article-title":"Serotonin and Norepinephrine Reuptake Inhibitors","volume":"250","author":"Shelton","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/13543784.11.10.1437","article-title":"Tricyclic antidepressants and fibromyalgia: What is the mechanism of action?","volume":"11","author":"Lawson","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"H\u00e4user, W., Urr\u00fatia, G., Tort, S., U\u00e7eyler, N., and Walitt, B. (2013). Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst. Rev., CD010292.","DOI":"10.1002\/14651858.CD010292"},{"key":"ref_29","first-page":"CD011735","article-title":"Selective serotonin reuptake inhibitors for fibromyalgia syndrome","volume":"2015","author":"Walitt","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","article-title":"Vortioxetine: A novel antidepressant for the treatment of major depressive disorder","volume":"14","author":"Gonda","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2019.12.002","article-title":"Ropinirole, a New ALS Drug Candidate Developed Using iPSCs","volume":"41","author":"Okano","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11682-015-9459-4","article-title":"Differential dopamine function in fibromyalgia","volume":"10","author":"Albrecht","year":"2016","journal-title":"Brain Imaging Behav."},{"key":"ref_33","first-page":"1","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"1","author":"Silber","year":"2016","journal-title":"Sleep Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","article-title":"Current approaches to the treatment of Parkinson\u2019s Disease","volume":"27","author":"Ellis","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.rhu.0000081264.26484.e5","article-title":"Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia","volume":"9","author":"Holman","year":"2003","journal-title":"J. Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","article-title":"Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia","volume":"146","author":"Nagakura","year":"2009","journal-title":"Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109975","DOI":"10.1016\/j.pnpbp.2020.109975","article-title":"Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy","volume":"103","author":"Micov","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_38","unstructured":"(2021, April 01). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020658s018s020s021lbl.pdf."},{"key":"ref_39","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/B978-0-7020-4086-3.00033-3","article-title":"Fibromyalgia","volume":"119","author":"Sumpton","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/hup.1029","article-title":"Fibromyalgia-pathways and neurotransmitters","volume":"24","author":"Stahl","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Paredes, S., Cantillo, S., Candido, K.D., and Knezevic, N.N. (2019). An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225729"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Maffei, M.E. (2020). Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217877"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpain.2008.12.008","article-title":"Changes in gray matter density in fibromyalgia: Correlation with dopamine metabolism","volume":"10","author":"Wood","year":"2009","journal-title":"J. Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpain.2006.05.014","article-title":"Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study","volume":"8","author":"Wood","year":"2007","journal-title":"J. Pain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2017.12.031","article-title":"Pain sensitivity in Parkinson\u2019s disease: Systematic review and meta-analysis","volume":"48","author":"Sung","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"dmm039396","DOI":"10.1242\/dmm.039396","article-title":"Sensory neuropathy and nociception in rodent models of Parkinson\u2019s disease","volume":"12","author":"Valek","year":"2019","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12640-020-00166-4","article-title":"Neuropathic Pain Dysregulates Gene Expression of the Forebrain Opioid and Dopamine Systems","volume":"37","author":"Piotrowska","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1111\/j.1460-9568.2007.05623.x","article-title":"Fibromyalgia patients show an abnormal dopamine response to pain","volume":"25","author":"Wood","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/14737175.8.5.781","article-title":"Role of central dopamine in pain and analgesia","volume":"8","author":"Wood","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kashyap, P., Kalaiselvan, V., Kumar, R., and Kumar, S. (2020). Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands towards Factors Implicated in Alzheimer\u2019s Disease. Molecules, 25.","DOI":"10.3390\/molecules25071609"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, L.M., Shi, S.D., Liu, Y., and Zou, Q. (2019). Bioactivity-Guided Isolation and Identification of New and Immunosuppressive Monoterpenoid Indole Alkaloids from Rauvolfia yunnanensis Tsiang. Molecules, 24.","DOI":"10.3390\/molecules24244574"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2011.13.1\/ccelano","article-title":"Depressogenic effects of medications: A review","volume":"13","author":"Celano","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.131.3411.1440","article-title":"Is reserpine tranquilization linked to change in brain serotonin or brain norepinephrine?","volume":"131","author":"Sulser","year":"1960","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2014.05.043","article-title":"Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice","volume":"86","author":"Klein","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bpa.12253","article-title":"Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson\u2019s Disease: New Perspectives to a Long-Standing Model","volume":"25","author":"Santos","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxicon.2014.01.015","article-title":"The effects of Ph\u03b11\u03b2, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model","volume":"81","author":"Castro","year":"2014","journal-title":"Toxicon"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jep.2010.08.045","article-title":"Comparative effects of Rauwolfia vomitoria and chlorpromazine on locomotor behaviour and anxiety in mice","volume":"132","author":"Bisong","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbr.2018.01.005","article-title":"Sleep architecture is altered in the reserpine-induced fibromyalgia model in ovariectomized rats","volume":"364","author":"Pellicer","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104673","DOI":"10.1016\/j.neuint.2020.104673","article-title":"Involvement of TRPV1 and the efficacy of \u03b1-spinasterol on experimental fibromyalgia symptoms in mice","volume":"134","author":"Fischer","year":"2020","journal-title":"Neurochem. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcp.2019.05.012","article-title":"Ameliorative effect of imperatorin in chemically induced fibromyalgia: Role of NMDA\/NFkB mediated downstream signaling","volume":"166","author":"Kaur","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fnins.2016.00283","article-title":"Commentary: Evaluation of Models of Parkinson\u2019s Disease","volume":"10","author":"Leal","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0091-3057(99)00240-3","article-title":"Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys","volume":"65","author":"Fukuzaki","year":"2000","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","first-page":"555","article-title":"Repeated treatment with a low dose of reserpine as a progressive model of Parkinson\u2019s dementia","volume":"32","author":"Ikram","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"850","DOI":"10.7326\/0003-4819-131-11-199912070-00009","article-title":"Management of Fibromyalgia","volume":"131","author":"Leventhal","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.neuroscience.2010.06.061","article-title":"Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats","volume":"169","author":"Oe","year":"2010","journal-title":"Neuroscience"},{"key":"ref_68","first-page":"526","article-title":"Psychosis and enhanced anxiety produced by reserpine and chlorpromazine","volume":"74","author":"Ogle","year":"1956","journal-title":"Can. Med. Assoc. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1744806918808987","DOI":"10.1177\/1744806918808987","article-title":"Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain","volume":"14","author":"Zuena","year":"2018","journal-title":"Mol. Pain"},{"key":"ref_70","first-page":"185","article-title":"Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study","volume":"21","author":"Adamo","year":"2020","journal-title":"Pain Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Adamo, D., Pecoraro, G., Coppola, N., Calabria, E., Aria, M., and Mignogna, M. (2020). Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis.","DOI":"10.1186\/ISRCTN13795228"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41401-020-0433-3","article-title":"D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice","volume":"42","author":"Tang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bja.2019.07.028","article-title":"Dopaminergic neurotransmission and genetic variation in chronification of post-surgical pain","volume":"123","author":"Joosten","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"ref_74","first-page":"409","article-title":"Treatment of fibromyalgia: A changing of the guard","volume":"1","author":"Holman","year":"2005","journal-title":"Womens Health"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/pmt-2016-0006","article-title":"Management of fibromyalgia syndrome in 2016","volume":"6","author":"Okifuji","year":"2016","journal-title":"Pain Manag."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.2042-7158.1967.tb08021.x","article-title":"The effect of reserpine and alpha-methyldopa on the analgesic action of morphine in the mouse","volume":"19","author":"Ross","year":"1967","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10880-013-9382-z","article-title":"Acute stress, depression, and anxiety symptoms among English and Spanish speaking children with recent trauma exposure","volume":"21","author":"Barber","year":"2014","journal-title":"J. Clin. Psychol. Med. Settings"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00296-018-4068-3","article-title":"The role of mirtazapine in patients with fibromyalgia: A systematic review","volume":"38","author":"Ottman","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/j.1526-4637.2006.00178.x","article-title":"Duloxetine and other antidepressants in the treatment of patients with fibromyalgia","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2017.11.003","article-title":"Revisiting the validity of the mouse forced swim test: Systematic review and meta-analysis of the effects of prototypic antidepressants","volume":"84","author":"Kara","year":"2018","journal-title":"Neurosci. Biobehav Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/acschemneuro.7b00042","article-title":"The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior","volume":"8","author":"Commons","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: Recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brainresbull.2007.05.004","article-title":"Involvement of dopamine (DA)\/serotonin (5-HT)\/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2\/D3 dopamine receptor agonist","volume":"74","author":"Dhir","year":"2007","journal-title":"Brain Res. Bull."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S1461145714000728","article-title":"Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain","volume":"17","author":"Mavrikaki","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00415-010-5879-7","article-title":"Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: A multicentre, randomized, placebo-controlled study","volume":"258","author":"Benes","year":"2011","journal-title":"J. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s002130050555","article-title":"Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test","volume":"136","author":"Lucki","year":"1998","journal-title":"Psychopharmacology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/JBCPP.2011.027","article-title":"Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats","volume":"22","author":"Ghorpade","year":"2011","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.31887\/DCNS.2015.17.3\/mbourin","article-title":"Animal models for screening anxiolytic-like drugs: A perspective","volume":"17","author":"Bourin","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Misztak","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/S1092852917000761","article-title":"Efficacy of vortioxetine in working patients with generalized anxiety disorder","volume":"24","author":"Christensen","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis","volume":"64","author":"Pae","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuropharm.2013.05.014","article-title":"Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice","volume":"73","author":"Guilloux","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_93","unstructured":"(2021, March 01). Available online: https:\/\/www.mayoclinic.org\/drugs-supplements\/ropinirole-oral-route\/side-effects\/drg-20066810?p=1."},{"key":"ref_94","unstructured":"(2021, March 01). Available online: https:\/\/parkinsonsnewstoday.com\/forums\/forums\/topic\/ropinirole-cause-of-shortness-of-breath-anxiety-like-symptoms-between-med-dose\/."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002130000485","article-title":"Anxiolytic profile of ropinirole in the rat, mouse and common marmoset","volume":"151","author":"Rogers","year":"2000","journal-title":"Psychopharmacology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.euroneuro.2017.08.427","article-title":"Striatal dopamine D2\/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response","volume":"27","author":"Sikora","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0091-3057(93)90525-X","article-title":"Anxiogenic-like effects induced by stimulation of dopamine receptors","volume":"45","author":"Simon","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00213-020-05452-9","article-title":"Vortioxetine administration attenuates cognitive and synaptic deficits in 5\u00d7FAD mice","volume":"237","author":"Jiang","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/acschemneuro.9b00386","article-title":"Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T+Itpr3tf\/J Mice","volume":"10","author":"Witt","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00210-013-0847-2","article-title":"Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice","volume":"386","author":"Gawlik","year":"2013","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"ref_101","first-page":"327","article-title":"Behavioral despair in mice: A primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2015.07.037","article-title":"Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor","volume":"99","author":"Siwek","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pbb.2005.04.015","article-title":"Anxiolytic-like effect of milnacipran in the four-plate test in mice: Mechanism of action","volume":"81","author":"Bourin","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuropharm.2017.07.029","article-title":"Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia","volume":"125","author":"Tejada","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar4402","article-title":"Animal models of fibromyalgia","volume":"15","author":"DeSantana","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.physbeh.2015.07.033","article-title":"Depressive-like symptoms in a reserpine-induced model of fibromyalgia in rats","volume":"151","year":"2015","journal-title":"Physiol. Behav."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/8\/2398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:50:26Z","timestamp":1760161826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/8\/2398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":106,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["molecules26082398"],"URL":"https:\/\/doi.org\/10.3390\/molecules26082398","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}